Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMI-TICLO trial)

Cardiovascular Revascularization Medicine

Volumn 15, Issue 5, 2014, Pages 284-288

  Winter, José Luis ^a,b   Lindefjeld, Dante Syvert ^a,b   Veas, Nicolás ^a,b   Guarda, Eduardo ^a,b   Valdebenito, Martín ^a,b   Méndez, Manuel ^a,b   Pérez, Osvaldo ^a,b   Zuanic, Karla ^a,b   Mestas, María ^a,b   Martínez, Alejandro ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL DR SÓTERO DEL RÍO   (Chile)

Author keywords

Clopidogrel; Microvascular perfusion; STEMI; Ticagrelor

Indexed keywords

CLOPIDOGREL; TICAGRELOR; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; HEART MUSCLE REPERFUSION; HUMAN; IMAGE ANALYSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MIDDLE AGED; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; FEMALE; MALE; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PROCEDURES; VERY ELDERLY;

ADENOSINE; ADULT; AGED; AGED, 80 AND OVER; ANGIOGRAPHY; ANGIOPLASTY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84907321046     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2014.07.001     Document Type: Article

References (23)

1. Svilaas T., Vlaar P.J., vander Horst I.C., Diercks G.F., de Smet B.J., van den Heuvel A.F., et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008, 358(6):557-567.
2. Gabriel H.M., Oliveira J.A., da Silva P.C., da Costa J.M., da Cunha J.A. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv 2006, 68(2):218-224.
3. Gurbel P.A., Bliden K.P., Butler K., Tantry U.S., Gesheff T., Wei C., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009, 120(25):2577-2585.
4. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045-1057.
5. van Giezen J.J., Sidaway J., Glaves P., Kirk I., Bjorkman J.A. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012, 17(2):164-172.
6. Guarda E., Prieto J.C., Sanhueza P., Dauvergne C., Asenjo R., Corbalán R. Guías 2009 de la Sociedad Chilena de Cardiología para el tratamiento del Infarto Agudo del Miocardio con supradesnivel del ST. Rev Chil Cardiol 2009, 28:223-254. [Ref Type: Generic].
7. Gibson C.M., Cannon C.P., Daley W.L., Dodge J.T., Alexander B., Marble S.J., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996, 93(5):879-888.
8. Gibson C.M., Cannon C.P., Murphy S.A., Ryan K.A., Mesley R., Marble S.J., et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000, 101(2):125-130.
9. Gibson C.M., de Lemos J.A., Murphy S.A., Marble S.J., McCabe C.H., Cannon C.P., et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 2001, 103(21):2550-2554.
10. Claeys M.J., Bosmans J., Veenstra L., Jorens P., De RaedtH, Vrints C.J. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. Circulation 1999, 99(15):1972-1977.
11. Angeja B.G., Gunda M., Murphy S.A., Sobel B.E., Rundle A.C., Syed M., et al. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 2002, 105(3):282-285.
12. Hamada S., Nishiue T., Nakamura S., Sugiura T., Kamihata H., Miyoshi H., et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. J Am Coll Cardiol 2001, 38(3):666-671.
13. Steg P.G., James S., Harrington R.A., Ardissino D., Becker R.C., Cannon C.P., et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010, 122(21):2131-2141.
14. Parodi G., Valenti R., Bellandi B., Migliorini A., Marcucci R., Comito V., et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013, 61(15):1601-1606.
15. Kunadian V., James S.K., Wojdyla D.M., Zorkun C., Wu J., Storey R.F., et al. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv 2013, 6(7):671-683.
16. Wittfeldt A., Emanuelsson H., Brandrup-Wognsen G., van Giezen J.J., Jonasson J., Nylander S., et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol 2013, 61(7):723-727.
17. Bonello L., Laine M., Kipson N., Mancini J., Helal O., Fromonot J., et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014, 63(9):872-877.
18. Niccoli G., Burzotta F., Galiuto L., Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009, 54(4):281-292.
19. Bonderman D., Teml A., Jakowitsch J., Adlbrecht C., Gyöngyösi M., Sperker W., et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002, 99(8):2794-2800.
20. Stone GW, Abizaid A, Silber S, Dizon JM, Merkely B, Costa RA, et al. Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial. J Am Coll Cardiol 2012; Sep 28. pii: S0735-1097(12):04506-8. [Epub ahead of print]. http://dx.doi.org/10.1016/j.jacc.2012.09.004.
21. Lindefjeld D.S., Guarda E., Mendez M., Martínez A., Pérez O., Fajuri A., et al. Microvascular coronary flow comparison in acute myocardial infarction angioplasty treated with a mesh covered stent (MGUARD stent) versus bare metal stent: MICAMI-MGUARD. Cardiovasc Revasc Med 2013, 14(1):4-8.
22. Kelbaek H., Terkelsen C.J., Helqvist S., Lassen J.F., Clemmensen P., Kløvgaard L., et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J Am Coll Cardiol 2008, 51(9):899-905.
23. Frobert O., Lagerqvist B., Olivecrona G.K., Omerovic E., Gudnason T., Maeng M., et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013, 369(17):1587-1597.